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Abstract 
The area of biomedical imaging is fast becoming an active focus for the utilisation of graphene 
within a variety of imaging modalities. Graphene can be oxidised to produce a material with a 
high degree of functionality and has led to its expansion as a platform for the immobilisation 
of fluorescent and radiolabelled molecules. Its large surface area has allowed graphene and its 
oxides to be modified with a variety of molecules that enhance biocompatibility, selectivity 
and therapeutic potential. This chapter highlights recent developments in the use of targeted 
fluorogenic or radiolabelled graphene materials that can be used to image cancers via 
fluorescence, PET & SPECT modalities. Key emphasis is placed on the nanocomposites that 
are designed to provide additional therapeutic effects. The capacity of these composites to be 
internalised by cells and tumours is discussed to appreciate the future perspective of graphene 
and its congeners as therapeutic multimodal imaging agents. 
 
 
 
Keywords: Graphene, Graphene Oxide, Bioimaging, Biosensing, Nanomedicine, Cancer 
Theranostic, PET, SPECT, Fluorescence, Radiolabelling.  
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Introduction 
A. The Problem 
Cancer has become a pervasive problem of modern society affecting the health of the global 
population year on year in an ever increasing manner. Hundreds of thousands of people are 
diagnosed with cancer every year in the UK alone. It is characterised by over 200 different 
types, each with its own symptoms, methods of diagnosis and treatment. The latest statistics 
indicate that in the UK alone there were over 330,000 new cases of cancer in 2011, of which 
over half of these cases were attributed to prostate, breast, lung and bowel cancer. During the 
period of 2009-2011, approximately a third of the diagnoses were in individuals above the age 
of 75.1a, 1b 
 
Figure 1: European age-standardised incidence rates for cancers excluding non-melanoma skin 
cancer, Great Britain, 1975-2011. Data were provided by the Office for National Statistics, ISD 
Scotland and Welsh Cancer Intelligence and Surveillance Unit on request, May - July 2013.   
One of the main reasons behind this increase in diagnosis is due to modern screening and 
imaging technologies, such as magnetic resonance imaging (MRI) and commuted tomography 
(CT) methods, which have allowed physicians to expose cases of cancer that would have 
previously remained undiagnosed. The other one is an ever ageing population that has made it 
necessary to anticipate further rises in cancer incidence that require broad and robust screening 
technologies in order to inform and assist medical professionals and their patients across the 
entire spectrum of cancer developments and treatments. Cancer is an extremely complex 
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degenerative condition, whereby each type of cancer is biologically different from another. 
Depending on the cell origin and the extent of mutagen exposure, certain cancers will 
demonstrate varying propensities for proliferation.2 For instance, cancers can differ in terms of 
their tissue origin, with sarcomas arising from connective tissue or muscle, whereas carcinomas 
come from epithelial cells. Each of these cancers can have a wide array of contributory genetic 
abnormalities that can influence the overall nature of the cancer malignancy. These factors 
make it difficult to identify the way the particular cancer cells are behaving and how they are 
likely to metastasize or damage the body. Without a full understanding of the physiology of 
the cancer, effective treatments remain elusive to develop. The highly individualised nature of 
cancer development and wide variation in tumour heterogeneity3 has led to the 
acknowledgment that an accurate determination of an individual’s specific state of cancer 
progression will allow clinicians to tailor their treatments to suit a particular patient’s needs. 
This will aid in achieving a more personalised approach towards the therapy and diagnosis of 
cancer.  
This is the primary principle of theranostics development whereby screening and diagnosis 
methodologies simultaneously incorporate therapeutic strategies in order to achieve a more 
rapid and efficient cancer diagnosis and treatment protocol.4 
MRI techniques have proven to be a quite effective method in cancer diagnosis due to its 
ability to provide detailed images of tissue and organs in a comparatively non-invasive 
manner.5 There is a relatively minimal risk to patients associated with use of the MRI contrast 
agent gadolinium chelate.6 However, despite its accuracy and considerable versatility with 
respect to identifying instances of cancer, it presents a very low sensitivity and there are still 
issues associated with incidental findings that can complicate the interpretation of resulting 
images. In addition, to date there are no instances of incorporating simultaneous therapeutic 
strategies within MRI imaging. On the other hand, it has become necessary to look to 
alternative imaging techniques and broaden the scope of molecules that have the capacity to 
not only screen and diagnose, but to also treat cancer to ultimately achieve the theranostics’ 
goals.  
Amongst the many several imaging modalities for cancer diagnosis and treatment, 
fluorescence imaging, Positron Emission Tomography (PET) and single photon emission 
computed tomography (SPECT) have garnered considerable research interest, due to the 
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availability of a wide selection of molecules with suitable properties for providing a good signal 
that can be exploited to image a variety of cancers.7  
Fluorescence techniques employ a number of well-established molecules directed to target 
cancer specifically, such as Rhodamine, derivatives of fluorescein and more recently near-infra 
red emitting cyanine dyes.8 The characteristic of these molecules to emit fluorescent and 
phosphorescent photons after excitation with wavelengths in the visible and near infra-red 
region of the spectrum has led to their conjugation to a variety of molecules in order to enhance 
their properties for cancer imaging and treatment. In particular, the use of near infra-red 
absorbing molecules has transformed the way in which cancer is visualised. Considering that 
large portions of tissue are transparent to near-infra red wavelengths, such fluorophores have 
allowed for deeper penetration into living tissue that effectively eliminates the background 
auto-fluorescence. Furthermore, the capacity for certain fluorophores to undergo intersystem 
crossing after excitation and achieve triplet excited states has led to their incorporation in 
simultaneous therapeutic strategies that rely on the generation of cancer targeting singlet 
oxygen species.9 
With respect to PET and SPECT imaging modalities, both of these techniques employ 
radioisotopes as a means of characterising cancers, based on the localisation of intravenously 
injected radiotracers. Typically, the chosen molecules are labelled with Oxygen-15, Fluorine-
18, Carbon-11 and Nitrogen-13 radioisotopes. However, the broad availability of a selection 
of isotopes within the field of nuclear medicine has led to the development of alternative 
metallic based radioisotopes with considerably longer half-lives than those of the 
aforementioned elements. These include various metallic complexes of copper, gallium, 
indium and technetium amongst others.10 Although these imaging modalities are very sensitive 
and quantitative, they possess a poor spatial resolution. The spatial resolution and detection 
capabilities of PET/SPECT imaging agents are key factors in determining their ultimate value 
towards cancer diagnosis. Current pre-clinical gamma detecting cameras can provide sub 0.5 
mm and 1-2 mm resolution for SPECT and PET scanners respectively. Furthermore, 
PET/SPECT techniques are now being incorporated into dual MRI or CT systems in order to 
gather more information about biological systems in the same spatial temporal environment.11  
The ability of imaging technologies to achieve both diagnosis and therapy is a considerable 
challenge that relies heavily on the capacity of the exploited molecules to express an inherent 
multitude of physical phenomena or to be easily conjugated to molecules that can provide the 
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additional therapeutic effect. More commonly, the imaging strategy is used to monitor the 
progress or efficacy of a separately administered therapeutic strategy rather than providing the 
therapeutic effect as well. However, the field of biological imaging is beginning to expand into 
the incorporation of graphene materials to achieve just such a goal. 
Since its discovery in 2004, graphene and the advent of its associated technologies have 
seen an incredible rise in research within a multitude of disciplines;12 from electronics,13 
materials chemistry,14 biosensing15, catalysis16 and now bioimaging. This is primarily due to 
its extensive array of impressive properties. Described as a single layer of sp2 hybridised carbon 
atoms arranged in a honeycomb like lattice, graphene is known to possess high intrinsic 
electron mobility,17 superior strength,18 high specific surface area,19 high thermal electronic 
conductivity20 as well as interesting optical properties such as high near infra-red absorbance 
in its oxidised derivatives.21 A considerable body of graphene related work for biological 
applications has utilised the oxidised variants of graphene because of the ease in which large 
quantities can be produced, superior solvent dispersibility, biocompatibility and ease of 
functionalisation.22 
Graphene and its oxidised derivatives have proven to be quite versatile materials when it 
comes to serving as platforms for the immobilisation and delivery of imaging and therapeutic 
agents in vitro and in vivo. The abundance of oxygen functional groups on graphene oxide has 
led to a wide variety of covalent strategies towards the immobilisation of imaging agents and 
bio-targeting molecules. However, active areas of research are dedicated to methods of 
immobilisation driven primarily by van der Waals and electrostatic interactions. This can 
potentially facilitate the formation of an extensive library of molecules aimed at achieving 
multifunctional Theranostics nanomaterials.23 
The capacity of graphene to provide a surface area and functional group targets makes it an 
obvious choice for the incorporation of multiple imaging agents, as well as bio-targeting and 
therapeutic molecules to achieve the Theranostic goals in cancer management. This opens up 
the potential for graphene as an imaging and therapeutic tool via multiple modalities. 
B. Probe Design towards a Solution 
The development of graphene oxide based probes, with the aim of achieving imaging via 
multiple modalities as well as additional therapeutic effects, requires a multifaceted approach 
to imaging and diagnostic probes’ design. A careful selection of molecules exhibiting the 
appropriate characteristics for imaging via fluorescence, PET and SPECT is required. The 
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chosen molecule will ultimately determine the method of immobilisation onto graphene oxide, 
whether it be a covalent or non-covalent strategy. For instance, numerous fluorophore 
compounds make use of the presence of π conjugation within their structures to attach to 
graphene through π-π interactions. Additionally, pre-derivatisation of the fluorophore with a 
biomolecule can eliminate the need for multiple conjugation strategies. In some cases, the 
strategy involves exploiting the varied charged nature of biomolecules to immobilise them via 
electrostatics separately. Quite frequently, fluorophores and biomolecules are covalently 
immobilised via peripheral carboxylic acid groups, which are introduced to graphene after 
oxidation. Among these molecules that possess fluorescence characteristics, varieties of them 
contain or can be synthesised to contain metals used in PET/SPECT based imaging 
modalities.24 Considerable bodies of work are also dedicated to labelling biomolecules with 
radioisotopes, with the modification of peptide sequences with technetium proving to be an 
active area of research.25 
 
Figure 2: Constituent components of targeted bioimaging probes. (V. Mirabello, D. G. 
Calatayud, R. L. Arrowsmith, H. Ge and S. I. Pascu, J. Mater. Chem. B, 2015, DOI: 
10.1039/C5TB00841G - Reproduced by permission of The Royal Society of Chemistry) 
With respect to fluorophore attachment to a graphene-based scaffold, a number of studies 
has exploited the tendency of graphene to act as an efficient quencher of fluorescence via 
Forster Resonance Energy Transfer (FRET). Some of these fluorophores may also demonstrate 
the ability to achieve triplet excited states.26 These two phenomena make graphene a potential 
candidate for the facilitation of photodynamic and photothermal therapeutic effects.27 
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Multimodal imaging and therapeutic intentions require key design features to be met if a viable 
imaging agent is to be achieved. 
a) Presence of a suitable signalling agent to facilitate the imaging, such as a radioactive 
isotope, fluorescent molecule or a combination of both. 
b) A biological molecule to impart cancer specificity onto the intended imaging agent. 
c) An appropriate linking strategy to attach the molecule to the surface of graphene oxide; 
tailoring or controlling its stability in biological media. 
d) Selection of imaging agent which allows additional phenomena that can be exploited 
to impart a therapeutic effect 
e) The probe must include a suitable means of retaining stable dispersions of graphene 
oxide in vitro/vivo. 
In this Chapter, the imaging agents that constitute the focus of our attention are typically 
fluorescent molecules or radiolabelled bioconjugates. The majority of the fluorophores 
discussed possess near infra-red absorbance characteristics and the PET/SPECT capability 
generally tends to come from the modification of an immobilised molecule with copper, 
gallium or indium. Particular attention is paid to peptide sequences and their versatility as 
cancer targeting biomolecules. 
Graphene Oxide as a Platform for Fluorescent and Radiolabelled Probes for 
Cancer Imaging and Therapeutic applications 
A. The Chemistry of Graphene and of Graphene Oxides 
Graphene is a 1 atom thick carbon allotrope material comprised of sp2 bonded carbon atoms 
arranged in a regular honeycomb like lattice structure28. Discovered in 2004 by Andre Geim 
and Dimitri Novosolev, single and few layer graphene has presented a number of exciting and 
valuable properties such as high electron mobility in ambient conditions29, tuneable optical 
properties30, tuneable band gap31, high mechanical strength18 and thermal conductivity20 
amongst others. 
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Figure 3: Idealised structure of a pristine graphene sheet containing honeycomb arrangement 
of hexagonal carbon moieties. 
 
A low cost carbon based material, such as graphene and its oxides, possessing the 
aforementioned properties, is an ideal candidate material for the development of imaging 
probes and biosensors for cancer associated with optical methods of transduction. There is a 
variety of graphene-based materials that are distinguished based on their method of production. 
Graphene can be produced via chemical vapour deposition (CVD) processes32 and mechanical 
exfoliation of bulk graphite and graphite oxide33. Large scale processing of graphene associated 
nanostructures is achieved by thermal, chemical and electrochemical reduction of graphene 
oxide.34 Unlike CVD derived or mechanically exfoliated graphene, graphene oxide and its 
reduced variants possess a significant number of defects as a result of the disruption of the sp2 
bonded planar network of carbon atoms. The oxidation of bulk graphite introduces sp3 domains 
as a result of the presence of extensive oxygen functionalities35.  
These oxygen functional groups present viable targets for the modification of the material 
with a variety of molecules which can ultimately serve the purpose of providing a bio-
functional material suitable for fluorescent, PET/SPECT imaging and Theranostic applications.  
This section will focus primarily on the varied chemistry of graphene oxide and how these 
aspects influence the immobilisation of optical and targeting agents. 
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Figure 4: Structure of graphene oxide containing oxygen functionalities across the basal plane 
and on the periphery. 
 
A considerable percentage of research has been devoted to graphene related materials over 
the last decade, since the publication of Novosolev and Geim’s seminal work reporting a field 
effect in atomically thin carbon films.36 Therefore, one might assume that the study of graphene 
materials is a relatively recent area. However, investigations into the chemistry of graphitic 
materials are thought to precede the 20th century. In 1859, B. C.  Brodie performed reactions 
with flake graphite with a focus towards determining the molecular weight of graphite.37 One 
particular reaction involved the addition of potassium chlorate to graphite in nitric acid. After 
four consecutive oxidative procedures, a plateau of oxygen concentration was reached with the 
resulting material having a Carbon: Hydrogen: Oxygen ratio of 61.04: 1.85: 37.11 and it was 
readily dispersible in water but not acidic media. It was therefore termed graphic acid. Latter 
improvements were made to this method by L. Staudenmaier through the addition of 
concentrated sulphuric acid and by splitting the addition of potassium chlorate into multiple 
events throughout the duration of the reaction38. More than half a century after these works, 
Hummers and Offeman went on to establish the basis for what has now become the most 
established method for the large scale production of oxidised graphite as a precursor to 
graphene oxide (GO). In this method potassium permanganate and concentrated sulphuric acid 
are added in order to generate a dimanganese heptoxide species that acts as an effective oxidant 
of the flake graphite (scheme 1).39 
 
 
Scheme 1: Generation of oxidising agent during Hummer’s method. 
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Having established effective methods of oxidising flake graphite, a significant body of work 
has focused on elucidating a reliable universal structural model for graphene oxide. This has 
proven to be a particularly challenging task, in large part due to the variation in atomic content 
of flake graphite derived from its amorphous berthollide mineral source. A further barrier to 
determining a general structure is the fact that the GO materials studied are usually derived 
from processes having modifications to the Hummers method, which vary from procedure to 
procedure. The following section describes some of the more established models developed for 
graphene oxide and the associated techniques used to establish the nature of its oxygen 
functional groups. 
The first concerted approach to developing a structural model for GO was performed by 
Hofmann and Holst. The structure they proposed contained repeating lattice units with epoxy 
groups littered across the basal plane of graphite conforming to a sp2 hybridized system. Reuss 
et al developed this model further by introducing hydroxyl groups into the structure proposed 
by Hofmann and Holst. This was also accompanied with a change in structure of the basal 
plane from a sp2 hybridised system to that conforming to a sp3 hybridisation.40 
 
Figure 5: Hofmann and Reuss structures proposed for GO, the former containing epoxides and 
the latter containing both epoxides and hydroxyl groups.  
 
This model retained the repeating unit nature of the Hofmann and Holst model, but the 
distinguishing feature was the suggestion of epoxide groups in the 1 and 3 positions of the 
cyclohexane moieties as well as hydroxyl groups in the 4th position. 
Latterly, Scholz & Boehm and Nakajima & Matsuo proposed slightly differing structures, 
with one possessing quinoidal species without epoxides or ethers41 and the latter containing a 
stage two graphite intercalation structure42. Beyond these models, Lerf and Klinowski have 
proposed a different structure. They performed extensive solid state Nuclear Magnetic 
Resonance (NMR) investigations on the products of various reactions with graphene oxide in 
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order to extract information regarding hydration characteristics and the material’s reactive 
functional groups. The key feature noted from these investigations was the suggestion of the 
presence of tertiary alcohols, epoxy groups and various alkenes evidenced by resonances 
situated around 60, 70 and 130 ppm respectively. Their work also explained the tendency for 
GO to stack due to the presence of hydrogen bonding facilitated by the alcohol and epoxide 
groups between the platelets of GO.43 This model largely conformed to previous models 
differing only in the suggestion that the ethers existed in the 1 and 2 positions as opposed to 
the 1 and 3 positions as suggested by earlier models. Lerf and Klinowski also re-evaluated the 
conclusions derived from the earlier spectroscopic studies to suggest that in addition to 
epoxides and tertiary alcohols, carboxylic acid groups also existed in relatively smaller 
amounts on the edges of graphitic planes.44 
Figure 6: Lerf and Klinowski model containing epoxides, tertiary alcohols and carboxylic acid 
groups on the edges of GO.34 
 
Facile and rapid routes to functionalising graphene oxide for biomedical applications 
Having established the presence of a variety of oxygen functional groups on GO, the 
material naturally becomes a promising candidate for various chemical functionalisations that 
would render it a far more valuable material for biomedical imaging and sensing applications. 
 
Carboxylic acid activation 
When considering the use of carboxylic acid groups as targets for functionalisation it is 
necessary to use an appropriate activating agent. Thionyl Chloride,45 EDC (EDC = 1-Ethyl-3-
(3-dimethylaminopropyl)carbodiimide),46 DCC (N,N'-dicyclohexylcarbodiimide) and HATU 
(1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate) are just some examples of compounds used for this purpose.47 Then, 
molecules containing amines and hydroxyls can be added to form amide or ester linkages. The 
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use of carbodiimides has proven to be a popular choice in regards to the conjugation of 
biomolecules to a variety of surfaces. This is in part due to this particular reagent facilitating 
the formation of what is known as a zero length cross-linker. In this methodology, two 
molecules are attached to each other via the formation of a bond that contains no extra 
interfering atoms.48 This is desirable in regards to the final application, as additional spacing 
atoms between two molecules may hinder the ultimate function of the hybrid molecule, which 
is of vital concern when establishing functional biomaterials. Carbodiimides are therefore a 
widespread choice because they are able to facilitate the creation of amide linkages between 
species containing carboxylic acids and amines. They are considerably versatile reagents in 
that they can be used to effectively couple peptides sequences, proteins and other complex 
biomolecules to each other as well as a variety of surfaces. 
EDC is one of the most widely used carbodiimides for coupling reactions involving 
biomolecules. EDC will react with a carboxylic acid containing molecule to create a stable 
ester intermediate. The addition of a nucleophilic amine containing molecule facilitates the 
formation of an amide bond with the loss of an isourea by-product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Schematic representation of reaction scheme to produce amide bonds via EDC 
mediated coupling adapted from reference 48.48  
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The primary concern with the use of this reagent is the potential for self-polymerisation in 
which the bio-molecule may react with another molecule of itself due to the presence of 
carboxylates and amines. 
Studies have been performed whereby carbodiimide activation approaches have been used 
to modify GO sheets with polyethylene glycol (PEG) as a means of developing a biocompatible 
drug delivery vector/vehicle for anti-cancer drugs.49 In this study in vitro tests were carried out 
in which it could be to demonstrate that the covalently functionalised GO served as a viable 
vector for the immobilisation of anticancer drugs via π-π stacking. The GO hybrid material was 
ultimately shown to possess a high performance towards the killing of human colon cancer 
cells. 
Carboxylic activation methods have also been used for the covalent attachment of 
porphyrins to GO as a means of developing light harvesting materials for photovoltaic 
applications.50 The overall broad applicability of carboxylic activation via carbodiimide 
mediated or alternative activation approaches demonstrates the suitability of these reagents for 
the development of zero length cross-linkers for fluorescent and bio-electronic applications. 
 
Epoxide ring opening reactions 
As discussed earlier, a significant number of structural models based on infra-red 
spectroscopic studies and solid state NMR investigations have suggested the existence of epoxy 
groups distributed along the basal plane of the graphitic domains. These are in a greater 
abundance with respect to the carboxylic acids and therefore present another attractive area for 
molecular functionalization.34 
In 2011, one study utilised an epoxide ring opening strategy with an amine containing ionic 
liquid in order to provide a suitably positive electrostatic charge for the immobilisation of a 
glucose oxidase enzyme.51 A relatively simple methodology in which the ionic liquid [1-(3-
aminopropyl)-3-methylimidazolium bromide] (NH2-IL) was added to a GO dispersion along 
with potassium hydroxide and with 24 hours of stirring overnight, led to the subsequent 
immobilisation of glucose oxidase into the IL-graphene surface. Ring opening strategies have 
also been used to impart photoluminescent properties onto graphene oxide.52 In this work 
alkylamines of varying chain length were used to remove the opportunity of recombination of 
electron-hole pairs as a result of the presence of both epoxy and carboxylic acid groups, which 
is largely seen as the reason for the lack of strong fluorescence emission characteristics in GO.53 
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Acylation reactions to form surface amides followed by nucleophilic ring opening aminations 
lead to the removal of both the carboxylic acid and epoxy groups, which in turn greatly 
enhanced the fluorescent quantum yields of GO. 
 
Non-covalent tagging strategies 
The extensive sp2 hybridisation of the planar graphitic domains opens up the opportunity 
for functionalisation via π-π stacking or van der Waals forces in the areas that lack the oxygen 
functionality or hydrogen bonds. 
Hunter and Sanders have described a model for understanding the interaction between 
separate aromatic systems. In general, the electron density derived from the π orbitals of 
aromatic rings creates a quadrupole moment possessing an overall partial negative and partial 
positive charge on top of aromatic faces and on the periphery respectively. When these 
moments come within a suitable distance, a face centred parallel stacking interaction can 
occur.54 The interaction between aromatic molecules that alternate in their extent of electron 
density is sometimes referred to as aromatic donor-acceptor interactions. Although there is still 
considerable debate in regards to the driving forces behind the interactions between aromatic 
molecules in close proximity to one another,55 it would still suffice to conclude that such 
interactions present an attractive strategy towards the construction of supramolecular 
assemblies based on aromatic graphitic and fluorescent bio-molecules. 
We have recently focused our research work on non-covalent strategies to functionalise the 
surface of GO with aromatic chromophores in particular with aryl thioacetate Zn(II) porphyrin. 
Porphyrins are aromatic, planar and electron-rich molecules well known for their high 
extinction coefficients and near infrared (NIR) emissions. A supramolecular self-assembly, 
based on donor-acceptor interactions, results in a new class of GO@Zn(II)-porphyrin 
nanohybrid forming a stable dispersion in the most common organic solvents. The morphology 
of such a supramolecular complex has been extensively investigated by atomic force 
microscopy (AFM) and transmission electron microscopy (TEM). These analyses, together 
with UV-Vis titrations, have demonstrated that a ground state Zn(II) porphyrin complex can 
interact with the π orbitals of aromatic rings of GO. On the other hand, fluorescent spectroscopy 
and time correlated single photon counting carried out on GO@Zn(II)-porphyrin complex and 
Zn(II) porphyrin have suggested that, upon excitation, an excited state Zn(II) porphyrin can 
also interact with GO forming a stable complex via FRET. The use of a NIR dye capable of 
16 
 
generating FRET in the presence of GO nanosheets can certainly be of great interest in the 
development of new forms of imaging/therapy probes.  
Various studies have now led to a beginning of an understanding of the complex 
mechanisms by which graphene can be internalised by a variety of mammalian cells. Uptake 
of graphene nanosheets has been studied by Portoles et al. in which osteoblasts, hepatocytes 
and macrophages were incubated with PEGylateda GO nanosheets modified with an 
fluorescein isothiocyanate (FITC) dye to trace their localisation in vitro.56 Cells were incubated 
with the GO conjugates, along with a number of endocytosis inhibitors in order to understand 
the pathways that influence the migration of GO into cells. They were able to show that 
micropinocytosis is the most prevalent means of uptake. Macropinocyctosis is a process in 
which a fluid containing vesicle, known as a micropinosome, breaks away from the cell surface 
and incorporates the material in question.57 The micropinosome along with its cargo is 
subsequently drawn into the interior of the cell. In addition to micropinocytosis, phagocytosis, 
microtubule and clathrin dependent mechanisms can also play a role in graphene endocytosis. 
Ultimately this study showed that there is a general method of cellular internalisation; however, 
there can be additional mechanistic pathways depending on the cell type. 
Nano-graphene oxide, i.e. a graphene oxide whose 3 dimensions are under 100 nm, has been 
reported as a viable facilitator of drug delivery and cellular imaging applications. In 2008, a 
study was carried out in which PEGylated nano-graphene oxide was used to image cells and 
deliver anti-cancer drugs. The GO materials that possessed fluorescent properties in the visible 
and near-infra red region were used to selectively image Raji-B cells via the detection of near 
infra-red photoluminescence.58 Furthermore, the physical adsorption of the anti-cancer drug 
doxorubicin via π-π interactions onto the nano graphene oxide with a cancer targeting antibody 
Rituxan was able to facilitate the selective killing of specific carcinoma in vitro. 
In summary, GO presents a number of options for functionalisation via various covalent and 
supramolecular interactions. The broad applicability of the resulting nano-materials from 
fluorescent materials, drug delivery vectors, electrochemical through to light harvesting 
applications enhances its viability as a candidate for the development of multifunctional 
imaging and therapeutic tools that exploit optical transduction methodologies. 
                                                          
a PEGylation is the process of both covalent and non-covalent attachment or amalgamation of polyethylene 
glycol (PEG) polymer chains to molecules and macrostructures, such as a drug, therapeutic protein or vesicle, 
which is then described as PEGylated 
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B. Fluorescence imaging and therapeutic applications of functional Graphene 
Oxide-based probes 
A fluorescent probe is a compound that possesses an intrinsic ability to emit fluorescent 
photons after excitation with an appropriate wavelength. Upon conjugation to a biomolecule 
via a reactive site on the fluorophore, the resulting modified biomolecule can be suitable for 
applications such as imaging and fluorescent based biosensors. Labelling biomolecules with 
fluorescent compounds is seen as an attractive option for the aforementioned applications 
because of their highly specific emission characteristics after excitation with light. 59 
The processes that occur in fluorescence during the absorption and emission of light can be 
illustrated by the Jablonski diagram (Figure 7). 
 
Figure 7: Jablonski diagram illustrating the various radiative and non-radiative decay 
processes occurring after excitation.(H. Xu, R. Chen, Q. Sun, W. Lai, Q. Su, W. Huang and X. 
Liu, Chemical Society Reviews, 2014, 43, 3259-3302 - Published by The Royal Society of 
Chemistry)60 
The initial transition denoted in the Jablonski diagram is the process of photon absorbance. 
During this event a photon of a specific energy is excited from a lower ground energy level to 
a higher energy state. The photonic energy is transferred to an electron, which then excites to 
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a heightened state depending on the energy transferred. The absorbance events occur quite 
rapidly in the region of 10-5 seconds.61 Once an electron has reached an excited state, the energy 
absorbed can be dissipated through the loss of a photon. This event is known as fluorescence 
and occurs at relatively slower timescales such as 10-9 to 10-7 seconds. Fluorescence 
phenomena tend to occur between the 1st excited electron level and the ground state. At higher 
energies, dissipation of the absorbed energy is more likely to occur via internal conversion or 
vibrational relaxation. During vibrational relaxation, the energy absorbed during excitation can 
be given to other vibrational modes as kinetic energy. Internal conversion also occurs when 
vibrational energy levels overlap with electronic energy levels allowing for transitions between 
vibrational states of different electronic levels.61 Finally, intersystem crossing can occur in 
which electrons in a singlet state transition to an excited triplet state. The transition down from 
an excited triplet state to a singlet ground state is responsible for phosphorescence phenomena. 
It is such excited state energy transitions that allow for photodynamic therapeutic strategies or 
fluorescence resonance energy transfer based in vitro/vivo recognition and imaging 
methodologies that will be the main focus of the first section of this review. 
C. Peptide Sequences for the Specific Targeting of Cancer and means to their 
incorporation into GO 
 
 
Figure 8: Scope of molecules available for graphene modification. (Reprinted from Y. Wang, 
Z. Li, J. Wang, J. Li and Y. Lin, Trends in Biotechnology, 2011, 29, 205-212, Copyright (2011), 
with permission from Elsevier)1c 
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During the process of developing functional nanomaterials for biological applications, it has 
been shown that it is essential to include in the probe composition a biomolecule to engender 
specificity. Over the years, various antibodies, deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA) molecules have been used to derivatise surfaces and other small molecules as a 
means of developing bio-targeting surfaces and molecules for applications ranging from 
electrochemical biosensors, drug delivery vehicles, radiolabelling and fluorescence imaging.62 
A significant body of work has focused on the use of peptide sequences as molecular targets 
for cancer Theranostics.63,64 Peptide sequences are seen as an alternative to antibody based 
targeting strategies due to their considerably smaller size in relation to their antibody 
counterparts used for similar applications. The large molecular weights of antibodies tend to 
result in difficulties when targeting large tumour masses and there are also issues associated 
with their non-specific uptake by the liver, spleen and bone marrow which further limit their 
effectiveness.65 Peptides are sequences of amino acids that can vary widely in size and function 
based on the number and type of amino acids attached to each other. Part of the reason for the 
utility of peptides in cancer Theranostics is associated with their ability to target specific 
receptors that are expressed on the cellular membranes of a variety of cancers. 
Recent work has demonstrated that relatively small peptides tend to assemble towards the 
edges or planar surfaces of graphene oxide via π-π interactions.66,67.68 Katoch et al. carried out 
studies in which they were able to show that the peptide sequence of GAMHLP-WHMGTLb 
transformed from an α-helix to a reticular structure when adsorbed on graphene surfaces.69 
Atomic level simulations have also demonstrated that peptides which possess α-helices tend to 
unfold and form amorphous dimers upon conjugation to graphenes. Studies have suggested 
that the phenomenon of α-helix unfolding begins at the C-terminus of the peptide and the 
degree of unfolding is largely influenced by the strength of the interactions between certain 
amino acids. 
Density functional theory (DFT) studies have also been used to develop a deeper 
understanding regarding the interaction of graphenes with amino acids and peptides. Kawazoe 
et al. have modelled the interaction of phenylalanine, histidine, tyrosine and tryptophan with 
graphene and carbon nanotubes. Their results suggest that the aromatic components of these 
                                                          
b A peptide sequence ZP-1. Mammalian zona pellucida (ZP) is an extracellular matrix surrounding and protecting 
mammalian and fish oocytes, which is responsible for sperm binding. ZP consists of three to four glycoproteins, 
called ZP1, ZP2, ZP3, ZP4 
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amino acids re-arrange themselves to a parallel conformation along the basal plane of the 
graphitic domains via π-π interactions. In addition to these theoretical studies, experimental 
investigations have probed the interaction of lysine, arginine, tryptophan and tyrosine with GO. 
They have also concluded that binding between amino acids and GO can be considerably 
influenced by π-π interactions. However, they also suggest that the positively charged side 
chains on lysine, histidine and arginine can bind to GO via additional electrostatic mechanisms. 
In general a large majority of studies associated with experimental and atomistic investigations 
have implicated the amino acid residues such as tryptophan as being the strong driving force 
behind the immobilisation of peptides to graphene and carbon nanotube surfaces.70,71,,72 
GO materials based on immobilised peptides are showing significant potential towards 
developing multifunctional and highly sensitive detection platforms. Recently dye-labelled 
peptides immobilised on GO surfaces have shown considerable promise towards developing 
multifunctional and highly sensitive detection platforms. The first reported study of a GO based 
sensing mechanism that utilised a non ssDNA molecule as a bio-recognition molecule was 
reported in 2011. In this work, a peptide labelled with fluorescein isothiocyanate (FITC) was 
used to target the serine protease thrombin.73 The use of this fluorophore facilitated 
fluorescence resonance energy transfer between the GO and the fluorescent peptide, allowing 
for the monitoring of protease activity. This work was able to demonstrate that the increase in 
fluorescence intensity had a direct correlation to the concentration of Thrombin. The 
fluorescence based detection mechanism allowed thrombin to be quantified in concentrations 
as low as 2 nM. Additionally, a fluorescence-based detection mechanism for Caspase-3 (a 
known mediator for the triggering and spread of apoptosis events) was recently developed. In 
this research a peptide sequence of Asp-Glu-Val-Asp with a fluorescein amidite (FAM) 
labelled lysine was bound to GO surfaces using EDC/NHS (EDC = 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide; NHS = N-Hydroxysuccinimide) activation approaches to 
produce a novel GO fluorescent peptide conjugate (Figure 9).74  
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Figure 9: Caspase-3 detection using GO–peptide conjugate and confocal fluorescence 
microscopy images of HeLa cells treated with 4 μM STS for 4 h after incubation. (Reprinted 
from H. Wang, Q. Zhang, X. Chu, T. Chen, J. Ge and R. Yu, Angewandte Chemie International 
Edition, 2011, 50, 7065-7069 Copyright (2011), with permission from Wiley)74 
The bio-fluorescent GO hybrid material was successfully taken up by cells, followed by 
cleavage of the dye labelled peptide by internal proteases. Cleavage of the bond released the 
dye labelled peptide from the quenching effects of GO allowing its fluorescence characteristics 
to be used as means of verifying and quantifying the presence of Caspase-3. The bio-conjugate 
material demonstrated a high degree of stability in water and cell growth media and a wider 
promise towards the applicability of peptide-GO conjugates as cancer sensing mechanisms. 
The majority of the examples discussed herein will focus primarily on peptide based methods 
of bio-targeting and how this ultimately influences the distribution of the probe in vitro/vivo 
and the effectiveness of the imaging modality. 
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D. Targeted Fluorescent Molecules anchored onto Graphene Oxide for Cancer 
Imaging and Therapy Applications 
Graphene has demonstrated a capacity to serve as an imaging, diagnostic and therapeutic 
platform in a variety of functional states. In some instances, it can be used in conjunction with 
other nanoparticles to form effective diagnostic tools. In 2014, Ji et al. developed a prognostic 
indicator for early-stage cancer based on a combined graphene-mesoporous silica nano-sheet.75 
The value of such a system with respect to the in situ detection of prognostically significant 
bio-markers was fully realised after assembling the graphene-silica (GS) platform with a 
polyethylene glycol derivatised hexapeptide (PEG-RWIMYF) that served as recognition 
mechanism cyclin A2 (Figure 10). This particular cyclin has been implicated in the deregulation 
of cyclin dependant kinase (CDK) activity and hence chromosomal instability and ultimately 
tumour proliferation.44 Initially, the GS surface was functionalised with amines which were 
then converted to carboxyls (COO-) to allow for the electrostatic capping adsorption of the 
positively charged peptide. Prior to this step, the mesoporous silica had been loaded with 
Rhodamine B.  
Upon specific binding to cyclin A2, the peptide capping agent was removed from the GS 
nano-surface allowing for the release of Rhodamine B, effectively acting as a turn on switch 
for the quenched fluorescence.  
 
Figure 10: Schematic illustration of the GS-based peptide probe for cyclin A2 detection. 
(Reproduced from Ref 75 with permission of The Royal Society of Chemistry)75 
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The tendency for graphene to act as an effective quencher, as well as its capacity to be 
functionalised to facilitate physisorption, allowed for the efficient intracellular delivery of the 
fluorescence based recognition imaging agent. This particular functional nano-system was able 
to demonstrate the in vitro concentration dependant detection of cyclin A2 in a variety of 
cancerous and healthy cell lines based on the observed fluorescence intensity. Furthermore, the 
probe could be used to monitor the efficacy of the anti-cancer drug doxorubicin (DOX). DOX 
is known to up-regulate the expression level of cyclin A2. Consequently, in cell lines that were 
treated with DOX a corresponding increase in situ fluorescence was observed. 
This multicomponent approach to graphene probe design is one example of how 
incorporating peptides and fluorophores opens up the opportunity to exploit cellular 
recognition mechanisms to not only image and detect diagnostically relevant biomarkers, but 
to also track the progress of therapeutic strategies. 
One of the more widely researched biomarkers for the screening of prostate cancer is 
Prostate Specific Antigen (PSA). PSA is a serine protease that is produced by both prostate 
carcinoma, as well as their healthy or benign counterparts. Currently, there is still a great deal 
of limitation associated with PSA diagnostic measures in that they regularly fail to provide a 
suitable degree of specificity with respect to identifying and distinguishing between prostate 
cancers based on their malignancy.76 The proteolytic active form of PSA has been shown to be 
a more effective discriminator of prostate cancers based on their metastatic potential.77 This 
has led to the development of fluorescence based peptide targeting methods that can facilitate 
the “on-off” switching signal for this particular active form of PSA. Feng et al. developed an 
imaging based sensing probe through the modification of GO via peptide derivatised 
fluorescein isothiocyanate.78 The peptide containing the sequence HSSKLQc has been shown 
to be selectively cleaved by the proteolytic form of PSA. The construction of this sensing probe 
was achieved via the π-π and electrostatic interactions between peptide labelled FITC and the 
GO surface. As the active PSA is bound to the nano-construct, the protease would cleave the 
peptide allowing for the release of the dye due to diminished electrostatic interactions and 
hence recover the FITC fluorescence that was quenched due to the close proximity of the GO.  
                                                          
c A peptide sequence that is selectively cleaved by the proteolytic form of the prostate specific antigen 
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Figure 11: Schematic illustration of FITC labelled peptide conjugate loading on GO 
surface. (Reproduced from Ref 78 with permission of The Royal Society of Chemistry)78  
This study showed that a rapid fluorescence response could be observed when the GO dye 
labelled peptide was exposed to varying concentrations of PSA, with a detection limit of 0.3 
nM. Quite crucially, they were able to demonstrate the effective detection of active PSA in 
urine samples despite the presence of a variety of interfering molecules such as CaCl2, MgCl2, 
L-histidine and glycine amongst others. This study ultimately showed that exploiting the charge 
transfer capacity of GO to induce quenching, can be used in conjunction with targeted dye 
based systems for the effective “on-off” detection/sensing of diagnostically relevant 
biomarkers. 
The utility of combined fluorophore, peptide and GO constructs has extended to the 
monitoring of peptide receptor interactions. Somatostatins are hormone receptors that play a 
role in the regulation of the endocrine system. They have been implicated in cell proliferation 
and are therefore of particular interest when aiming to characterise a variety of cancers.79 
Octreotide is an 8 amino acid cyclic peptide sequence consisting of FCFWKTCTd. It is known 
to serve as an effective ligand for somatostatins and as such has led to its employment in 
graphene based recognition systems for imaging and sensing. Bianying et al. developed an 
imaging based sensory platform to characterise the aforementioned peptide-receptor 
interactions based on the combination of a FITC dye labelled octreotide (FOC) (Figure 12).80 
The FOC conjugate was adsorbed to the surface of GO and enhanced via the positively charged 
nature of the lysine residue, as well as the π-π interactions associated with the tryptophan and 
phenylalanine residues. The presence of these particular residues demonstrated that the FOC 
molecule could readily bind to the surface of GO with efficient quenching and adsorption 
                                                          
d Octreotide an 8 amino acid cyclic peptide sequence. It is known to serve as an effective ligand for somatostatins 
and as such has led to its employment in graphene based recognition systems for imaging and sensing 
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kinetics. After exposure of FOC to its antibody counterpart (anti-octreotide – AOC), the 
corresponding competitive interaction forced the release of FOC from the surface of GO 
allowing for the re-emergence of its fluorescence.  
 
Figure 12: 3-D Structure of Octreotide and schematic illustration of the concept of using 
FITC–Octreotide and GO to detect peptide–receptor interactions. (Reprinted with permission 
from F. Bianying, G. Linjie, W. Lihua, L. Fan, L. Jianxin, G. Jimin, F. Chunhai and H. Qing, 
Analytical Chemistry, 2013, 85, 7732-7737. Copyright (2013) American Chemical Society).80 
A greater signal to noise ratio was also noted for the total observed fluorescence in vitro 
when GO was included in the probe construct to suppress cellular auto-fluorescence. A linear 
relationship of AOC detection was observed based on the total fluorescence intensity to 
concentrations as low as 2 ng/ml. This specific peptide has been used to image the cancer cells 
and track the movement of the biomolecular interactions. AR42J rat pancreatic cells with a 
high expression of somatostatin receptors showed strong in vitro fluorescence upon release of 
FOC from the GO surface after receptor binding. This was in stark contrast to the significantly 
diminished fluorescence in CHO cell lines that possess a lower expression of somatostatin 
receptors. Ultimately, the study demonstrated that the combination of specific peptide 
interactions in conjunction with dye and GO molecules can serve to image and sense 
biomolecular interactions that are relevant to cancer development. 
One of the key challenges of developing Theranostic imaging agents for cancer based on 
GO materials is associated with enhancing the ease at which it can be dispersed in biological 
media. Many studies have utilised PEGylated GO to achieve just this purpose. However, the 
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utility of dendrimer type molecules extends to not only enhancing the stability of GO 
dispersions, but to also providing additional functional group anchor points. Dendrimers can 
serve to provide a branched architecture with a variety of functional groups for the 
immobilisation of a number of imaging and targeting agents.81 Wate et al. developed a GO 
system in which the dendrimer PAMAM G4 was used as an interface to facilitate the 
incorporation of a cyanine dye and magnetic Fe3O4 nanoparticles.
82 The inclusion of magnetic 
nanoparticles enhanced the capacity to direct the cellular localisation via the application of an 
external magnetic field. This work focused primarily on covalent methods to develop the nano-
construct. Glutathione (GSH) was used as a spacer/linker molecule to attach Fe3O4 and a 
cyanine dye to the GO surface via EDC carbodiimide activation protocols. 
 
Figure 13: Schematic of multicomponent magneto-dendritic graphene oxide nanosystem 
consisting of PAMAM G4 dendrimer (G4), Cyanine 5 (Cy), and Fe3O4 (Fe) 
nanoparticles.82 
 The resulting nano-construct was tested in vitro to characterise its capacity to image cells, 
as well as the resulting cellular viability after prolonged incubation. These tests were able to 
demonstrate successful uptake of the probe in MCF-7 breast cancer lines after dendrimer 
mediated dispersion in aqueous solution. The attachment of the cyanine dye facilitated 
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successful NIR imaging of cells with predominant localisation within the cytoplasm. Despite 
the multicomponent nature of the nano-probe little to negligible cytotoxicity was observed.  
The value of graphene oxide and its reduced derivatives extends beyond its capacity to be 
readily functionalised, in that it possesses intrinsic near infra-red absorbance properties. As 
alluded to in the introduction, this is of particular value with respect to imaging and therapeutic 
applications, primarily because the majority of living tissue is transparent to near infra-red 
light. Photothermal therapy relies on the capacity of the resulting heat generated from near 
infra-red light absorption as a means of achieving photoablation which ultimately leads to 
cancer cell death.83 Therefore, if selective uptake of graphene by cancer cells and tumours can 
be achieved there is potential for highly efficient imaging and photothermal therapeutic 
strategies.  
Robinson et al. employed nano-dimensional reduced graphene oxide with NIR absorbance 
characteristics that had been further functionalised with RGD (arginylglycylaspartic acid) 
targeting peptides and an additional cyanine dye (cy5) to further enhance NIR absorption. RGD 
peptides are known to target αvβ3 integrinse distributed along the membrane of cancer cells.84 
The derivatisation of the nRGO with RGD via supramolecular PEGylation resulted in a higher 
confocal fluorescence signal compared to the non-targeted nano-form used as a control (Figure 
                                                          
e A type of integrin that is a receptor for vitronectin 
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14). 
 
Figure 14: Schematic illustration of peptide and dye immobilisation on GO via PEG 
derivatisation. (Reprinted with permission from J. T. Robinson, S. M. Tabakman, Y. Liang, H. 
Wang, H. Sanchez Casalongue, D. Vinh and H. Dai, Journal of the American Chemical Society, 
2011, 133, 6825-6831. Copyright (2011) American Chemical Society)84 
This suggested that modifying nano surfaces with RGD like peptides is a viable means of 
enhancing uptake in vitro. The nano-conjugates also demonstrated minimal toxicity in human 
breast cancer cell lines. Furthermore, the targeted nano-construct could also be used to load 
non-covalently the anti-cancer drug doxorubicin via aromatic stacking reinforced with 
additional supramolecular interactions. The combination of the targeted nano-conjugate and 
therapeutic doxorubicin effects allowed for the further reduction in the doses required for the 
respective photothermal and chemotherapeutic agents. 
The need to ensure the retention of the stability of graphene based imaging probes is one of 
the key drivers behind the regular inclusion of certain dispersing agents such as PEG. However, 
naphthalene diimides are a particular class of fluorescent aromatic molecules that have 
demonstrated extensive utility in solubilising carbon allotropes and other aromatic systems.85 
Naphthalene derived molecules possessing donor-π-acceptor structures have shown promise as 
platforms for the design of two photon probes for a variety of biological targets. In a study by 
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Kim et al. a series of naphthalene based fluorophores was developed that could visualise and 
ultimately detect intracellular free metal ions, acidic vesicles and lipid rafts to 300 µm depths 
inside live tissue samples.86 In this work, two photon microscopy was used to demonstrate that 
the wide two photon cross sections of the naphthalene fluorophores were suitable for obtaining 
bright two photon images at low concentrations upon binding with intracellular ions/molecules 
that triggered detectable emission events. The study also demonstrated that such fluorescent 
probes possessed high cell permeability, selectivity towards cytosolic and membrane bound 
cellular constituents and an overall high photostability. 
1,4,5,8 – Naphthalenediimides (NDIs) are a group of planar, electrochemically active 
aromatic molecules distinguished by their naphthalene core and diimide nitrogens. 
Functionalisation via the diimide nitrogens results in naphthalene derivatives possessing 
variable absorption and emission characteristics. Generally, the attractive optical properties can 
be attributed to the presence of extended aromatic π conjugated systems. NDIs free of 
substitution on the naphthalene core tend to absorb only in the UV region.87 Extending the π 
conjugation via the addition of extra aromatic groups on the diimide nitrogens can improve 
absorption characteristics as is the case with perinones, which have phenylene diamine 
substituents on the diimide nitrogens and have been used as dyes and pigments as early as the 
1950s.88 The structure of NDIs also provides them with the ability to form supramolecular 
assemblies based on donor acceptor interactions. The aromatic and electron deficient 
characteristics render them with the ability to form face centred aromatic interactions. This 
particular property opens up avenues for functionalising GO via π-π stacking interactions.55 
Previous work within the group developed a facile method for the supramolecular 
complexation of phenylalanine substituted NDI molecules to single walled nanotubes 
(SWNTs) towards applications in cell imaging and drug delivery.85a This work demonstrated 
that the NDI molecules could wrap around SWNTs via supramolecular host-guest interactions 
based on π-π stacking. Two photon fluorescence lifetime imaging (2P-FLIM) demonstrated 
that the NDI molecule could retain a certain degree of fluorescence upon complexation to the 
SWNTs (Figure 15).  
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Figure 15: X-ray structure of NDI unit cell fragment proposed structure of a fragment of 
NDI@SWNT composite: molecular mechanics minimized representation of NDI stacks self-
assembled on the surface of a [10:10] SWNT fragment.(Reprinted from Z. Hu, G. D. Pantoş, 
N. Kuganathan, R. L. Arrowsmith, R. M. J. Jacobs, G. Kociok-Köhn, J. O'Byrne, K. Jurkschat, 
P. Burgos, R. M. Tyrrell, S. W. Botchway, J. K. M. Sanders and S. I. Pascu, Advanced 
Functional Materials, 2012, 22, 503-518. Copyright (2012), with permission from Wiley)85a 
Furthermore, it was demonstrated that functionalisation of SWNTs with the NDIs reduced 
the cytotoxic properties of the nanotubes and could be internalised within cancerous and non-
cancerous cell lines, thus establishing the supramolecular complexes as potential cell imaging 
probes. 
The use of NDI molecules has also been extended to incorporate targeting peptides for more 
specific imaging strategies for cancer (Scheme 3). We recently developed an NDI based 
imaging probe for the targeted imaging of cancer cells based on RGD peptide sequence.89 
Similar to the previous studies mentioned, the RGD sequence was used to target αvβ3 integrins 
more effectively. The over expression of αvβ3 integrins has been implicated in the tumour 
progression and metastasis in a number of cancers during tumour angiogenesis. Consequently, 
we synthesised a cyclic RGD variant and coupled it to a tryptophan tagged naphthalene 
diimide. Probing of the fluorescent characteristics of these molecules in PC-3 prostate cancer 
and non-cancerous FEK-4 cell lines was carried out via confocal and fluorescence lifetime 
imaging strategies (Figure 16).  
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Scheme 3: Synthesis of tryptophan–NDI–RGDfK.89 
 
Figure 16: Two-photon laser confocal fluorescence with λex = 810 nm. A typical 
micrograph of PC-3 cells incubated for 20 min at 37 °C with tryptophan tagged NDI (100 μM 
in 1 : 99% DMSO : EMEM) showing compound localisation in vesicular regions in the 
cytoplasm: lifetime mapping (a), the intensity image  and the corresponding average τ lifetime 
distribution curve and lifetime scale-bar.(Z. Hu, R. L. Arrowsmith, J. A. Tyson, V. Mirabello, 
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H. Ge, I. M. Eggleston, S. W. Botchway, G. Dan Pantos and S. I. Pascu, Chemical 
Communications, 2015, 51, 6901-6904 - Reproduced by permission of The Royal Society of 
Chemistry).89 
These studies revealed the successful uptake of the NDI-peptide conjugate within the 
cytoplasm of the exposed cells. One of the key findings was a narrowing of the excitation 
wavelength of the NDI after derivatisation with cyclic RGD to a region of the spectrum that 
avoided interfering cellular auto fluorescence. This supports the notion that RGD based NDI 
fluorescent imaging probes can be used to achieve more specific tracing and characterising of 
αvβ3 integrin expression in vitro. 
The previously mentioned dendrimer immobilisation strategy has also been used to facilitate 
a synergistic imaging and photothermal therapeutic effect by incorporating targeted 
phthalocyanine dyes onto GO surfaces. Taratula et al. utilised a polypropylene imine dendrimer 
to immobilise the dye molecules, PEG chains and luteinizing hormone releasing hormone 
(LHRH) peptide to selectively target ovarian cancer.90 This particular design allowed for GO 
to demonstrate its capacity to facilitate photodynamic therapy, as well as photothermal therapy. 
Near infra-red radiation of the phthalocyanine allowed for heat generation as energy transferred 
between the excited dye and the GO. Additionally, the dye could also achieve a triplet excited 
state which facilitated the formation of reactive oxygen species that created a photodynamic 
therapeutic effect. These combined strategies allowed for enhanced killing capability (90-95 
%) at low dye and graphene concentrations. In vivo studies also confirmed the ability of the 
probe to image cancer tumours in mice. 
The exploitation of FRET to enhance photothermal therapy via NIR dyes and GO extends 
to probe design with much simpler assemblies. Guo et al. conjugated the NIR dye cypatef to 
GO via a PEG linker. Upon irradiation of the dye, FRET induced an enhanced photothermal 
effect that was sensitive to pH.91 The dye-graphene conjugate demonstrated enhanced 
accumulation capacity in the tumours of mice, despite no specific derivatisation of the probe 
with a targeting biomolecule (Figure 17).  
Additionally, the rapid clearance of the probe from normal tissue has also been 
demonstrated. In vivo studies showed remarkable tumour necrosis and regression 2 days after 
injection and no tumour re-growth 22 days after injection. This was not the case for control 
                                                          
f A reactive carbocyanine dye, which is derived from indocyanine green 
33 
 
studies performed in absence of the dye. The GO-PEG construct alone demonstrated reasonable 
tumour re-growth within a 22 day period post-injection. This confirmed that the effective 
tumour ablation was ultimately due to the photothermal therapeutic effects facilitated by the 
presence of the dye and its capacity to undergo FRET with GO. 
 
Figure 17: Schematic illustration of GO-Cypate conjugate and in vitro/vivo nano-conjugate 
localisation images. (Reprinted from M. Guo, J. Huang, Y. Deng, H. Shen, Y. Ma, M. Zhang, 
A. Zhu, Y. Li, H. Hui, Y. Wang, X. Yang, Z. Zhang and H. Chen, Advanced Functional 
Materials, 2015, 25, 59-67. Copyright (2015), with permission from Wiley)91 
The examples described clearly present graphene as a versatile platform for the 
immobilisation of a broad range of molecules capable of therapeutic and diagnostic goals. 
These molecules range from a variety of fluorescent dye molecules, solubility enhancing 
polymers, through to bio-targeting molecules and therapeutic agents. The presence of innate 
near infra-red absorption characteristics, enhanced by further derivatisation with NIR dyes 
facilitates photothermal and photodynamic therapeutic effects that have expanded the scope of 
the benefits of using GO in cancer imaging modalities. 
 
F. Labelling of Graphene Oxide for PET/SPECT Radioactive Imaging and 
Tracing in vivo. 
 
The primary techniques of note when discussing emission tomography based methods of 
imaging, are Positron Emission Tomography (PET) and Single Photon Emission Computed 
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Tomography (SPECT). These techniques rely on the use of gamma ray emissions from 
radioactive materials as a means of visualising a variety of organs, and therefore tumour 
masses. Unlike some fluorescence based imaging modalities, gamma rays can travel through 
biological tissue with comparative ease. SPECT agents exploit radiopharmaceuticals that emit 
a single gamma ray photon per radioactive decay event. However, the radioisotopes used in 
PET modalities must be positron emitters. During radioactive decay, a positron is emitted from 
the nucleus of the radioisotope. The positron will then come into contact with an electron 
leading to annihilation and the subsequent release of two photons (Figure 18). Upon injection 
of a targeted radiotracer molecule, imaging projections of cross-sectional slices of the organs 
are generated and a tomographical representation is created from the reconstruction of the 
constituent images.92 
 
Figure 18: Schematic illustration of processes occurring during PET imaging.  
Typical positron emitters and their respective half-lives include 18F (t1/2 – 110 min), 11C (t1/2 
– 20.4 min), 15O(t1/2 – 124 s), 13N (t1/2 – 9.96 min), whereas common single photon emitters are 
99mTc(t1/2 – 6.02 h), 201Ti(t1/2 – 73.1 h), 123I (t1/2 – 13.2 h), 131I (t1/2 – 8.02 days), 111In (t1/2 – 2.83 
days), and 67Ga (t1/2 – 78.3 h).10 The following section will describe some examples of how 
these radioisotopes can be used in conjunction with other molecules to facilitate radiolabelled 
tracing and imaging of cancer in vivo. 
At this point it is clear that graphene possesses immense potential with respect to the 
immobilisation of a variety of molecules for a number of imaging and therapeutic applications. 
Over recent years this has been extended to PET based imaging modalities with 66Ga. 66Ga is 
of particular interest for GO mediated PET imaging strategies due to its longer half-life (9.5 h) 
with respect to 68Ga (68 min), a half-life that is relatively complimentary to the in vivo kinetics 
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of GO. One of the more common chelators of gallium radioisotopes is 1,4,7-triaxacyclononane-
1,4,7-triacetic acid (NOTA).93 To this end, Hong et al.94 covalently linked and amine 
terminated PEG for the immobilisation of 66Ga labelled NOTA that had been previously 
derivatised with an antibody that targets CD105 (endoglin) expression on the endothelial cells 
of tumours subject to proliferation.95 The resulting pharmacokinetics and capacity for tumour 
targeting was evaluated via PET imaging in mice carrying murine breast tumours (Figure 19). 
 
Figure 19: In vivo PET/CT imaging of 66Ga-labeled GO conjugates in 4T1 tumour-bearing 
mice and representative PET/CT images of 66Ga-NOTA-GO-TRC105 in 4T1 tumour-bearing 
mice at 3 h post-injection. (Reprinted from H. Hong, Y. Zhang, J. W. Engle, T. R. Nayak, C. 
P. Theuer, R. J. Nickles, T. E. Barnhart and W. Cai, Biomaterials, 2012, 33, 4147-4156. 
Copyright (2012), with permission from Elsevier)94a 
The radiolabelled GO composite showed a rapid and stable tumour accumulation rate over 
the course of a 24 hour period post injection. This particular study was also able to demonstrate 
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the suitability of the targeting agent, as histological studies showed there was no GO uptake in 
the tumours of mice that had been administered with the conjugate without CD105 targeting 
antibody. The ability to label GO with 66Ga poses considerable opportunity for further study 
with respect to elucidating the long term outcome and biodistribution of GO due to its superior 
half-life allowing for more prolonged studies. This may provide more valuable information 
about the state of tumour development and hence facilitate improved imaging and therapeutic 
intervention. 
This particular strategy towards radiolabelling has also been used to facilitate the inclusion 
of 64Cu within the targeted GO-NOTA construct.96 This immuno-construct possessing a 
slightly longer half-life (12.7 h) to its 66Ga counterpart showed significant uptake within the 
tumours, as well as the liver spleen and intestines which is not uncommon for intravenously 
injected nanomaterials that are cleared through the hepatobiliary system.  
 
Figure 20: In vivo PET/CT imaging of 64Cu-labeled GO conjugates in 4T1 tumour-bearing 
mice and histological studies on cross-sections from specific organs. (Reprinted with 
permission from H. Hong, K. Yang, Y. Zhang, J. W. Engle, L. Feng, Y. Yang, T. R. Nayak, S. 
Goel, J. Bean, C. P. Theuer, T. E. Barnhart, Z. Liu and W. Cai, ACS Nano, 2012, 6, 2361-
2370. Copyright (2012) American Chemical Society).94b 
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Ultimately, these works demonstrate that active and broad labelling of GO can be achieved 
with a number of radioisotopes provided there is a suitable chelator for the attachment to GO. 
The capacity to radiolabel graphene has also extended to the use of 125I isotopes in order to 
study the localisation and general biodistribution of graphene materials after oral 
administration or injection. Yang et al. used 125I to label PEGylated nanographene oxide 
(nRGO-PEG).97 The in vivo biodistribution of labelled GO variants was assessed after oral 
administration to mice. Considerable levels of radioactivity were observed in the stomach and 
intestines. However, no radioactivity was monitored in the organs of the mice one week post 
consumption (Figure 21).  
 
Figure 21: Photos of dissected mice and stained liver slices of mice injected with GO, nGO-
PEG, RGO-PEG, and nRGO-PEG at the dose of 50 mg/kg. (Reprinted from K. Yang, H. Gong, 
X. Shi, J. Wan, Y. Zhang and Z. Liu, Biomaterials, 2013, 34, 2787-2795. Copyright (2013), 
with permission from Elsevier).97 
The biodistribution of intravenously administered 125I-labelled GO varied in that the nano-
construct predominantly localised within the liver and spleen. This study established that the 
in vivo behaviour of graphene nanomaterials was highly dependent on size, surface 
modification and method of administration. Previous studies by the same group have used 125I 
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labelling of defect sites or edges of GO in conjunction with polyethylenimine, doxorubicin and 
plasmid DNA. This allowed for the active tracing of the efficiency of in vitro plasmid DNA 
transfection and combined therapeutic drug delivery. 
111In isotopes are frequently used for the radiolabelling of SPECT imaging applications and 
are currently being investigated as potential agents for the radio-tracing of GO based materials 
in vivo. Cornelissen et al. radiolabelled the metal ion chelator, 2-(4-amino benzyl)-diethylene-
triamine pentaacetic acid (p-NH2-BnDTPA) that was subsequently π-π stacked to the surface 
of nGO.98 The radiolabelled nano-construct was then derivatised with the antibody 
trastuzumab, an agent for the specific targeting of HER2 receptors over-expressed on breast 
cancers. 
SPECT imaging of the radiolabelled immmuno-constructs demonstrated tumour uptake in 
mouse xenografts. However, a quicker rate of uptake was observed for the radiolabelled probe 
without GO.  
Tumour uptake of the non-specific control was markedly lower than the uptake of its 
antibody conjugated counterpart. The diminished uptakes of the nano-probe without GO 
ultimately indicate that there is a complimentary relationship between the nano-graphene and 
the antibody. This work also demonstrated that another advantage of nGO based radiolabelled 
immune-constructs in PET/SPECT is associated with the relative ease at which other molecules 
could be attached, such as anti-cancer drugs and photosensitizers for combined therapy and 
imaging via multiple modalities. 
A significant advance in the field of the GO functionalization has been recently made by Feng, 
Dani and collaborators.99 In 2014, the authors described the use of metallic complexation of 
2,2’:6’, 2’’-terpyridine (tpy) with metal ions (Fe and Ru) as a driving force for 3D self-
assembling of GO structures. Tpy functionalised GO was obtained by reacting carboxy and 
epoxy groups of GO with an amine-functionalised terpyridine. The functionalization of GO 
with N3 donor ligands may open up new aspects of the technetium and rhenium chemistry. Re 
and Tc complexes bearing N3 ligands have been reported in the past. It is known that the three 
molecules of water in [99Tc(CO)3(H2O)3]
+ can be replaced by a very wide range of terdentate 
ligands.100,101 A GO functionalised with N3 donor ligands could effectively combine the 
potential of GO as delivery platform and the use of 99Tc as a radiopharmaceutical agent.  
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Imaging with 99mTechnentium is still used in the majority of nuclear medical investigations and 
it has been estimated that around 30-40 millions of technentium scans are annually performed 
across the world.100  
 
Scheme 4: Synthetic route towards the functionalisation of GO with terpyridine molecules. 
(Reprinted from S. Song, Y. Xue, L. Feng, H. Elbatal, P. Wang, C. N. Moorefield, G. R. 
Newkome and L. Dai, Angewandte Chemie International Edition, 2014, 53, 1415-1419. 
Copyright (2014), with permission from Wiley).99  
Conclusions and Future Prospects 
In the past three decades significant progresses have been made in the field of diagnosis and 
treatment of cancer tumours. By virtue of advanced bioimaging techniques such as MRI, PET 
and SPECT, it has become possible to increase the efficacy of cancer screening and detect 
cancers in tissue and organs even before symptoms appear. MRI techniques have emerged as 
one of the most promising bioimaging techniques providing detailed images of tissue and 
organs. MRI agents can modify the relaxation protons in the tissue and organs which induce 
changes in the MR signal intensity and therefore imaging contrast. Other methods of 
characterising tumours involve optical fluorescence imaging, which usually involve the use of 
small organic molecules or nanoparticles that behave as fluorophores. Nuclear medicine 
tomography is probably the most sensitive method for quantitative measurement in vivo and 
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has been extensively investigated worldwide by chemists and physicians in recent years. One 
of the benefits of PET and SPECT is that, unlike MRI or fluorescence, these techniques do not 
necessitate excitation or an external source of incident energy. The source of signal is generated 
from the radioisotopes employed in the screening analysis. In the past decade, many research 
groups have focused their attention on developing medical and diagnostic multimodality 
systems. As nanotechnology has progressively gained serious attention and new surface 
functionalization methodologies have been established, the challenge of the research 
community is to incorporate therapeutic and multimodal bioimaging probes in one single 
nanosystem. In this sense, GO and its derivatives, perhaps, represent one of the most promising 
materials to behaves as a platform for bioimaging and vectors for delivery. In this review, we 
have showed that graphene oxide can be functionalised by using synthetic approaches in order 
to covalently immobilise chemical species of relevance for imaging and tumour screening. The 
so called defects of the GO surface can be easily functionalised with fluorophores, 
biomolecules or organic ligands for metal chelation. The latter aspect could potentially open a 
new prospective in the use of GO as a scaffold for inorganic radioactive metal complexes 
having applicability in nuclear medicine tomography.  
The functionalization of GO can also be achieved by decorating its surface with 
biocompatible polymers that, although not directly involved in the imaging process, can be of 
great benefit to the biocompatibility, distribution and excretion of the probe. The intrinsic 
aromatic nature of GO can also be used to simplify the chemistry of surface functionalization. 
Indeed, a great variety of organic molecules, including fluorophores, can self-assemble around 
GO sheets by virtue of π-π stacking or van der Waals forces to generate supramolecular 
adducts. The intrinsic near infra-red absorbance properties of GO make this derivative of 
carbon one of the materials of choice for optical microscopy and imaging. Moreover, the tissue 
distribution and excretion of chemically functionalised GO have been recently explored and 
discussed.102 The work of Bianco and Kostarelos have demonstrated that particular derivatives 
of GO undergo rapid and significant urine excretion. This work will surely have significant 
implications for the use of GO in vivo and for general medical treatments. Much remains to be 
developed in the use of GO and carbon allotropes in the context of screening and tumour 
therapy but it is undisputable that much progress will be achieved considering the growing 
interest that GO is generating within the scientific community. 
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List of abbreviations 
 
 2P-FLIM   Two photon fluorescence lifetime imaging microscopy 
 AFM:    Atomic force microscopy 
 AOC:    Anti-octreotide 
 CD105:   Endoglin 
 CDK:    Cyclin dependant kinase 
 CT:    Commuted tomography 
 CVD:    Chemical vapour deposition 
 Cy5:    Cyanine dye 
 DCC:    N,N'-dicyclohexylcarbodiimide 
 DFT:    Density functional theory 
 DNA:    Deoxyribonucleic acid 
 DOX:    Doxorubicin 
 EDC:    1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
 FAM:    Fluorescein amidite 
 FITC:    Fluorescein isothiocyanate 
 FOC:    Fluorescein isothiocyanate dye labelled octreotide 
 FRET:    Forster Resonance Energy Transfer 
 GO:    Graphene oxide 
 GS:    Graphene-silica 
 GSH:    Glutathione 
 HATU:   1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo 
[4,5-b]pyridinium 3-oxid hexafluorophosphate 
 HER2:    Human epidermal growth factor receptor 2 oncogen 
 IL:    Ionic liquid 
 LHRH:   Luteinizing hormone releasing hormone 
 MRI:    Magnetic resonance imaging 
 NDI:    Naphthalenediimide 
 nGO:    Nano graphene oxide 
 NHS:    N-hydroxysuccinimide 
 NIR:    Near infrared 
 NMR:    Nuclear Magnetic Resonance 
 NOTA:   1,4,7-triaxacyclononane-1,4,7-triacetic acid 
 nRGO:    Nano reduced graphene oxide 
 PAMAM G4:   A polyamidoamine dendrimer of fourth generation 
 PEG:    Polyethylene glycol 
 PEG-RWIMYF:  Polyethylene glycol modified specific hexapeptide 
 PET:    Positron Emission Tomography 
 p-NH2-BnDTPA  2-(4-amino benzyl)-diethylene-triamine pentaacetic acid 
 PSA:    Prostate Specific Antigen 
 RGD:    Arginylglycylaspartic acid 
 RNA:    Ribonucleic acid 
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 SPECT:   Single photon emission computed tomography 
 ssDNA :   Single-stranded deoxyribonucleic acid 
 STS:    Staurosporine 
 SWNT:   Single walled nanotube 
 TEM:    Transmission electron microscopy  
 Tpy:    2,2’:6’, 2’’-terpyridine   
 TRC105:   Anti-endoglin antibody 
